Valuation: Inventiva

Market Cap 943M 1.08B 870M 802M 1.51B 104B 1.54B 10.4B 4.09B 50.88B 4.05B 3.96B 175B P/E 2026 *
-5.47x
P/E 2027 * -5.1x
Enterprise Value 775M 887M 715M 659M 1.24B 85.43B 1.27B 8.55B 3.36B 41.84B 3.33B 3.26B 144B EV / Sales 2026 *
115x
EV / Sales 2027 * 3.08x
Free-Float
89.08%
Yield 2026 *
-
Yield 2027 * -
1 day+4.31%
1 week+6.97%
Current month+23.91%
1 month+27.88%
3 months-17.22%
6 months-30.12%
Current year+1.14%
1 week 3.57
Extreme 3.57
4.04
1 month 2.88
Extreme 2.88
4.04
Current year 2.88
Extreme 2.88
6.2
1 year 2.64
Extreme 2.645
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
13.18
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 2025-09-30
Director of Finance/CFO 59 2026-04-21
Chief Tech/Sci/R&D Officer 56 2025-07-29
Director TitleAgeSince
Director/Board Member 75 2017-01-31
Director/Board Member 63 2019-05-26
Director/Board Member 52 2024-04-30
Date Insider Type Main position Quantity % Market Cap.
1/10/26 Others

Executive/Senior Manager

50,000 0.0262%
1/10/26 Others

Head of Human Resources

25,000 0.0131%
1/10/26 Others

Chief Operating Officer

25,000 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
+4.31%+6.97%+43.53%+10.53% 1.08B
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.06%-1.66%+41.05%+166.47% 23.46B
Weighted average by Cap. -2.77%-2.31%+40.14%+143.49%

Financials

2026 *2027 *
Net sales 6.73M 7.7M 6.21M 5.73M 10.79M 742M 11.03M 74.25M 29.21M 363M 28.93M 28.3M 1.25B 109M 124M 100M 92.34M 174M 11.96B 178M 1.2B 471M 5.86B 467M 456M 20.17B
Net income -150M -171M -138M -127M -240M -16.49B -245M -1.65B -649M -8.07B -643M -629M -27.8B -102M -117M -94.49M -87.09M -164M -11.28B -168M -1.13B -444M -5.53B -440M -430M -19.02B
Net Debt -168M -192M -155M -142M -269M -18.46B -274M -1.85B -727M -9.04B -720M -704M -31.12B -608M -696M -561M -517M -974M -66.98B -996M -6.7B -2.64B -32.81B -2.61B -2.55B -113B
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
73
Date Price Change Volume
26-07-17 €3.990 +4.31% 440,690
26-07-16 €3.825 -1.16% 194,994
26-07-15 €3.870 +1.31% 246,378
26-07-14 €3.820 +2.00% 357,604
26-07-13 €3.745 +0.40% 243,336
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.990EUR
Average target price
9.634EUR
Spread / Average Target
+141.46%

Quarterly revenue - Rate of surprise